Pharmafile Logo

Conference research case study

How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event


Our client had recently conducted a series of clinical trials with its breakthrough cardiovascular product, resulting in outcomes data which had the potential to give it a more competitive edge and successfully differentiate it against their closest competitor.

Communication strategies and marketing messages were to be crafted using the outcomes data which our client planned to launch at the European Society of Cardiology (ESC) annual congress. As a result, our client wanted to understand in detail the impact of their data on physicians’ perceptions of them.

In addition, with medical conferences representing a considerable investment in terms of time and resources, research was required to provide an understanding of what different aspects of the ESC annual conference meant to our clients key customers and the overall impact of the company’s presence on company perception.

Find out how we helped our client: https://bit.ly/2KuGas1

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Pegasus’s Approach to Measurement Wins 3 Gold’s at 2014 AMEC International Summit in Amsterdam

Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam

Pegasus Crowned Health Consultancy of the Year at 2014 Sabre Emea Awards

Brighton consultancy adds top honour to its award wins

Pegasus shortlisted for ‘Consultancy of the year’ at 2014 Communique Awards

Brighton-based independent healthcare specialist looks to add award to growing list of accolades

Pegasus Moves to Brighton

Top UK Healthcare Communications Consultancy Moves to Brighton

Warehousing of HCV patients reaches new high

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.

Patient Power: Too Much of a Good Thing?

Mary Assimakopoulos, reveals findings from the company’s Therapy Watch market research data, investigating patient behaviour in Crohn’s Disease and discusses how pharma can benefit from improved patient understanding